drugset / Trial / NCT05083078
A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis
RandomizedParallel-groupOpen-labelBasic science
Summary
The purpose of this study is to assess the tissue distribution of guselkumab and risankizumab in healthy participants (Part 1) and psoriatic arthritis (PsA) participants (Part 2 and Part 3).
Timeline
- Start
- 2021-11-04
- Primary completion
- 2022-07-01
- Completion
- 2022-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Guselkumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Risankizumab | Monoclonal antibody | — | Subcutaneous |